NEW CHALLENGES IN DIAGNOSIS AND TREATMENT OF LIVER DISEASE

Jerusalem, January 30-31, 2013
Venue: Hadassah Hospital Auditorium, Ein-Kerem, Jerusalem

DAY 1: JANUARY 30, 2013
15:00 Opening remarks • Welcome, The Organizing Committee
Professor Ehud Kokia, Director General, Hadassah Medical Organization-HMO
Professor Shlomo Mor-Yosef, Director, National Insurance Institute – Israel
Dr. Yair Birnbaum, Medical Director, Maccabi Healthcare Services

SESSION 1: Chairmen • Scott Friedman, Michal Carmiel
15:30 Quantifying hepatic steatosis • Mark Thursz
16:00 Long-term perspective of NAFLD in Israel • Ran Oren
16:20 Oral immune therapy for NASH • Yaron Ilan
16:40 Novel NLG4 dependent NK recognition in NAFLD • Rifaat Safadi

17:00 Coffee break

SESSION 2: Chairmen • Saif Abu-Mouch, Eyal Shteyer
17:30 Vitamin D prevents liver fibrosis in vivo and in vitro model but does not ameliorate established cirrhosis • Shimon Reif
17:50 Understanding the mechanism of acetaminophen toxicity: Why so many controversies? • Oren Shibolet

DAY 2: JANUARY 31, 2013
09:00 Welcome by the president of the Israel Association for the Study of the Liver • Ziv Ben-Ari

SESSION 3: Chairmen • Didier Samuel, Yaron Ilan
09:05 New tools for diagnosis and management of hepatic fibrosis • Scott Friedman
09:35 Immune modulation of hepatic fibrosis • Rifaat Safadi
09:55 Nucleic acid screening for hepatitis viruses in the blood bank • Harvey Alter
10:25 Safety of blood products in Israel • Vered Yahalom

10:45 Coffee break

SESSION 4: Chairman • Yaakov Naparstek, Assy Nimer
11:15 Epidemiology of hepatitis B and C in Israel • Eli Zuckerman
11:35 Prevention and treatment of viral hepatitis in Israel 1972-2012 • Daniel Shouval
11:55 Prevention of HBV graft re-infection after liver transplantation • Norah Terrault
12:25 Inhibition of hepatitis C virus by vitamin D in vitro and in vivo • Ran Tur-Kaspa
12:45 New Prospects for HCV eradication post liver transplantation • Didier Samuel

13:25 Lunch

SESSION 5: Chairman • Andrew Burroughs, Massimo Colombo
14:30 A review of the EASL, AASLD and APASL guidelines for the diagnosis of HCC • Massimo Colombo
15:00 90Ytrium radiotherapy for hepatocellular carcinoma • Andrew Burroughs
15:30 Ten year experience in treatment of hepatocellular carcinoma at Hadassah • Izhar Levy
15:50 Molecular and Cellular Mechanism in HCC • Ethan Galun

SESSION 6: Chairman • Michael Manns, Allan Bloom
16:10 Management of vascular liver disease • Dominique Valla
16:40 Diagnosis and management of overlap syndrome • Michael Manns
17:10 Non invasive monitoring of activity & staging of liver disease • Ziv Ben-Ari

Closing remarks • Ran Oren and Rifaat Safadi

Endorsed by the European Association for the Study of the Liver, Israel Association for the Study of the Liver, The Hebrew University, Hadassah Faculty of Medicine and Hadassah Medical Organization

For registration see web address (registration fees not required)

Platinum
Gold
Silver
Bronze

הנשפים מחמש שוויי

http://www.events.ortra.com/vigilant2013/